Pandion Therapeutics

Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory disease and organ transplants. Our localized approach represents a significant change from the systemic immunosuppression of conventional medicines, which often have dose-limiting safety concerns and can cause serious infections and cancer. Furthermore, through tissue-specific therapeutic targeting, Pandions approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. We aim to shift the paradigm and create a new generation of drugs...

Pandion therapeutics's revenue is 11m - 100m

Pandion therapeutics has 51 - 200 employees.